HLA-S - major histocompatibility complex, class I, S (pseudogene) Gene
Also Known as HLA-17
Species: Homo sapiens
Gene Type: pseudo
Gene ID: 267015
Related Diseases
| Diseases | Alias | |
|---|---|---|
| Prolymphocytic Leukemia |
|
|
| Autoimmune Hepatitis |
|
|
| Diseases | Alias | |
|---|---|---|
| Waldenstroem'S Macroglobulinemia |
Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B1455 | Clindamycin | Inhibitor | 99.90% | Yes |
| HY-N7118 | Clindamycin hydrochloride monohydrate | Inhibitor | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99339 | Tebentafusp | 99.90% | Unkown |
Clinical Phase
Bioactive MoleculesInhibitory Antibodies
(5)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P99573 | Tebotelimab | 99.52% | Phase 3 | |
| HY-P99551 | Tosatoxumab | 95.00% | Phase 3 | |
| HY-P990061 | Polzastobart | Inhibitor | 97.81% | Phase 2 |
| HY-P991610 | S-095029 | Inhibitor | / | Phase 2 |
| HY-P991366 | IBI-397 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(94)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-161111 | KVS0001 | Inhibitor | 99.14% | Unkown |
| HY-P10493 | NY-ESO-1 (157-165) peptide | 99.75% | Unkown | |
| HY-150749A | ODN D-SL03 sodium | 98.57% | Unkown | |
| HY-P1826 | CLIP (86-100) | 98.39% | Unkown | |
| HY-P5425A | Tetanus Toxin (830–844) TFA | 96.13% | Unkown | |
| HY-P1745 | InsB (9-23) | Ligand | 98.98% | Unkown |
| HY-P11303 | PADRE peptide | Ligand | 98.28% | Unkown |
| HY-P1780A | CEF20 TFA | 99.32% | Unkown | |
| HY-103333 | Arvanil | 99.1% | Unkown | |
| HY-P5470 | LMP2A (426-434) | Inducer | 96.09% | Unkown |
| HY-157269 | J10-1 | 99.92% | Unkown | |
| HY-N2245 | Schisandrone | Inhibitor | 99.78% | Unkown |
| HY-P10493A | NY-ESO-1 (157-165) peptide TFA | 97.62% | Unkown | |
| HY-P10664 | EBV EBNA3B (416-424) | Inhibitor | 99.52% | Unkown |
| HY-P1778A | HPV16 E7 (86-93) TFA | 98.01% | Unkown | |
| HY-P1919 | [Asp371]-Tyrosinase (369-377), human | 99.66% | Unkown | |
| HY-P3813 | Tyrosinase (206-214), human | 99.19% | Unkown | |
| HY-106187 | MART-1 (27-35) (human) | 98.60% | Unkown | |
| HY-173526 | H052 | Inhibitor | 98.18% | Unkown |
| HY-P1855 | HER2/neu (654-662) GP2 | 98.26% | Unkown | |
| HY-P5475 | BMLF1 (280–288) | 98.19% | Unkown | |
| HY-RS06217 | HLA-G Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-B1455S | Clindamycin-d3 hydrochloride | Inhibitor | 99.62% | Unkown |
| HY-106187B | MART-1 (27-35) (human) TFA | 98.12% | Unkown | |
| HY-138794B | XL177B | 99.36% | Unkown | |
| HY-150749 | ODN D-SL03 | Inducer | 99.82% | Unkown |
| HY-B1455S1 | Clindamycin-13C,d3 | Inhibitor | 99.94% | Unkown |
| HY-N10116A | Calamenene | / | Unkown | |
| HY-P11084 | WT1 126-134 peptide | 98.89% | Unkown | |
| HY-P11280A | PRAME peptide (425-433) acetate | Degrader | 98.16% | Unkown |
| HY-P11379 | ELTLGEFLKL | Modulator | 99.42% | Unkown |
| HY-P4032 | HCV Peptide (35-44) | 99.67% | Unkown | |
| HY-P5898 | Z-Val-Val-Nle-diazomethylketone | Inhibitor | / | Unkown |
| HY-RS06211 | HLA-DRB1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-106156 | Allotrap 07 | / | Unkown | |
| HY-150740 | ODN 21595 | Inhibitor | / | Unkown |
| HY-159123 | KHK-6 | Inhibitor | / | Unkown |
| HY-176784 | Human MOG-specifying DNA | / | Unkown | |
| HY-180609 | TCR-IN-2 | Inhibitor | / | Unkown |
| HY-D3334 | PE-CF594 | / | Unkown | |
| HY-P10593 | Influenza A NP (383-391) (HLA-B27) | / | Unkown | |
| HY-P10662 | HLA-B*0801-binding EBV peptide | / | Unkown | |
| HY-P10663 | EBV EBNA3A (379-387) | / | Unkown | |
| HY-P10835 | LAG-3 cyclic peptide inhibitor C25 | Inhibitor | / | Unkown |
| HY-P10994 | Eps8 peptide 327 | / | Unkown | |
| HY-P11084A | WT1 126-134 peptide acetate | 99.12% | Unkown | |
| HY-P11089 | TP53 neoepitope | Substrate | / | Unkown |
| HY-P11090 | TpD | / | Unkown | |
| HY-P11127 | MBP (111-129) | / | Unkown | |
| HY-P11179 | VTEHDTLLY | / | Unkown | |
| HY-P11340 | VMAPRTLFL | Ligand | / | Unkown |
| HY-P11383 | AIM2-derived decapeptide | / | Unkown | |
| HY-P11390 | BAGE (2-10) | Ligand | / | Unkown |
| HY-P11434 | Adipophilin-derived peptide | Ligand | / | Unkown |
| HY-P11437 | GFKQSSKAL | Ligand | / | Unkown |
| HY-P11713 | EBNA3B 399-408 | / | Unkown | |
| HY-P11714 | EBNA3 246-254 | / | Unkown | |
| HY-P1700 | BCMA72-80 | / | Unkown | |
| HY-P1757 | HIV p17 Gag (77-85) | Inhibitor | / | Unkown |
| HY-P1778 | HPV16 E7 (86-93) | / | Unkown | |
| HY-P1780 | CEF20 | / | Unkown | |
| HY-P1835 | CEF8, Influenza Virus NP (383-391) | / | Unkown | |
| HY-P1857 | CEF7, Influenza Virus NP (380-388) | / | Unkown | |
| HY-P1881 | HPV16-E711-20 epitope | / | Unkown | |
| HY-P1890 | CEF14, EBV Rta Protein (28-37) | / | Unkown | |
| HY-P1901 | Insulin alpha-chain (1-13) | / | Unkown | |
| HY-P3248 | J5 peptide | / | Unkown | |
| HY-P3742 | Tyrosinase (192-200), human mouse | / | Unkown | |
| HY-P5294 | YLLEMLWRL | Inhibitor | / | Unkown |
| HY-P5478 | Influenza virus PA (46-54) | / | Unkown | |
| HY-P5482 | Epstein-barr virus BRLF1 (134-142) | / | Unkown | |
| HY-P5503 | Pol (476-484), HIV-1 RT Epitope | / | Unkown | |
| HY-RS06196 | HLA-A Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06197 | HLA-B Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06198 | HLA-C Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06199 | HLA-DMA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06200 | HLA-DMB Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06201 | HLA-DOA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06202 | HLA-DOB Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06203 | HLA-DPA1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06204 | HLA-DPB1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06205 | HLA-DQA1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06206 | HLA-DQA2 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06207 | HLA-DQB1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06208 | HLA-DQB2 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06209 | HLA-DQB3 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06210 | HLA-DRA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06212 | HLA-DRB3 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06213 | HLA-DRB4 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06214 | HLA-DRB5 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06215 | HLA-E Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06216 | HLA-F Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-150740A | ODN 21595 sodium | Inhibitor | / | Unkown |
| HY-168384 | M04 | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(14)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990832 | Anti-MHC Class I Antibody (W6/32) | Inhibitor | 95.00% | Unkown |
| HY-P990189 | Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) | 95.00% | Unkown | |
| HY-P991750 | Anti-pan MHC Class II (HLA II) Antibody (IVA12) | Inhibitor | 99.27% | Unkown |
| HY-P990714 | Obertamig | Inhibitor | 95.803% | Unkown |
| HY-P992111 | Elfritatug | Inhibitor | 98.98% | Unkown |
| HY-P991590 | 1D09C3 | / | Unkown | |
| HY-P992018 | Anti-HLA-G Antibody | Inhibitor | / | Unkown |
| HY-P992377 | HY-0102 | / | Unkown | |
| HY-P992388 | IO-108 | Inhibitor | / | Unkown |
| HY-P991247 | Anti-HLA-A2 (Hu8F4) | Inhibitor | / | Unkown |
| HY-P991787 | Anti-HLA-A2 Antibody (BB7.2) | Inhibitor | / | Unkown |
| HY-P991837 | Anti-HLA-DP Antibody (B7/21) | Inhibitor | / | Unkown |
| HY-P991844 | Anti-HLA-DQ Antibody (1a3) | Inhibitor | / | Unkown |
| HY-P992017 | Anti-HLA-C Antibody | Inhibitor | / | Unkown |